Faculty Opinions recommendation of SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717993199.793487855 ◽

2013 ◽

Author(s):

J Michael Kilby

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Download Full-text

Efficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive Persons

HIV Clinical Trials ◽

10.1310/weqg-qthl-dl3x-ftxc ◽

2004 ◽

Vol 5 (6) ◽

pp. 361-370 ◽

Author(s):

R.D. MacArthur ◽

L. Chen ◽

G. Peng ◽

R.M. Novak ◽

M. van den Berg-Wolf ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Efficacy And Safety ◽

Nonnucleoside Reverse Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitor ◽

Download Full-text

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(11)70249-3 ◽

2012 ◽

Vol 12 (1) ◽

pp. 27-35 ◽

Author(s):

Jean-Michel Molina ◽

Anthony LaMarca ◽

Jaime Andrade-Villanueva ◽

Bonaventura Clotet ◽

Nathan Clumeck ◽

...

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Clinical Infectious Diseases ◽

10.1093/cid/cis1203 ◽

2013 ◽

Vol 56 (11) ◽

pp. 1637-1645 ◽

Author(s):

R. Campo ◽

E. DeJesus ◽

U. F. Bredeek ◽

K. Henry ◽

H. Khanlou ◽

...

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Download Full-text

Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens

JAIDS Journal of Acquired Immune Deficiency Syndromes ◽

10.1097/qai.0b013e318074eff5 ◽

2007 ◽

Vol 45 (4) ◽

pp. 401-410 ◽

Author(s):

Martin Markowitz ◽

Leonard N Slater ◽

Robert Schwartz ◽

Powel H Kazanjian ◽

Bruce Hathaway ◽

...

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Term Efficacy ◽

Download Full-text

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkp146 ◽

2009 ◽

Vol 64 (1) ◽

pp. 118-125 ◽

Author(s):

R. Landman ◽

C. Capitant ◽

D. Descamps ◽

C. Chazallon ◽

G. Peytavin ◽

...

Keyword(s):

Protease Inhibitor ◽

Inhibitor Therapy ◽

Protease Inhibitor Therapy ◽

Efficacy And Safety ◽

Download Full-text

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(18)30091-2 ◽

2018 ◽

Vol 5 (7) ◽

pp. e347-e356 ◽

Author(s):

Eric S Daar ◽

Edwin DeJesus ◽

Peter Ruane ◽

Gordon Crofoot ◽

Godson Oguchi ◽

...

Keyword(s):

Protease Inhibitor ◽

Efficacy And Safety ◽

Phase 3 ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1088945.542078 ◽

2007 ◽

Author(s):

Jonathan Schapiro

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty of 1000 evaluation for Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717952336.793467488 ◽

2012 ◽

Author(s):

Joe Eron

Keyword(s):

Protease Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Download Full-text

Stereoselective synthesis of N-Boc-O-benzyl-(4S,5S)-5-amino-4-hydroxy-6-phenylhexanoic acid, the hydroxyethylene isosteric moiety of potent HIV-1 protease inhibitor

Tetrahedron Letters ◽

10.1016/s0040-4039(00)85991-2 ◽

1991 ◽

Vol 32 (16) ◽

pp. 1897-1898 ◽

Author(s):

Tk Chakraborty ◽

Kiran Kumar Gangakhedkar

Keyword(s):

Protease Inhibitor ◽

Stereoselective Synthesis ◽

Download Full-text

Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection

Evidence-Based Medicine ◽

10.1136/ebmed-2016-110464 ◽

2016 ◽

Vol 21 (5) ◽

pp. 184-184

Author(s):

Diego Ripamonti

Keyword(s):

Maintenance Therapy ◽

Protease Inhibitor ◽

Triple Therapy ◽

Cost Effective ◽

Protease Inhibitor Monotherapy ◽

Download Full-text